# PROCEPT BioRobotics® to Report Second Quarter 2025 Financial Results on August 6, 2025
Canonical URL: https://biopharmsignal.com/news/PRCT/procept-biorobotics-to-report-second-quarter-2025-financial-results-on-august-6--7a3af3bc
Ticker: PRCT
Company: PROCEPT BioRobotics
Source: PROCEPT BioRobotics
Published: 2025-07-21 20:03 EST
## Summary

PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused...

## Article Body
PROCEPT BioRobotics ® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2025 after market close on Wednesday, August 6, 2025. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the below links:

Webcast link for interested listeners : https://edge.media-server.com/mmc/p/apg8aowj

Dial-in registration for sell-side research analysts: https://register-conf.media-server.com/register/BI6a34da2819a549879a20996d9920dc2f

Live audio of the webcast will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com .

An archived recording will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com . Each webcast will be available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation PROCEPT BioRobotics’ mission is to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. PROCEPT BioRobotics manufactures the AQUABEAM ® and HYDROS™ Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact: Matt Bacso VP, Investor Relations and Business Operations m.bacso@PROCEPT-BioRobotics.com
## Recent Company News
- 2026-07-14 20:05 EST — [PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026](https://biopharmsignal.com/news/PRCT/procept-biorobotics-to-report-second-quarter-2026-financial-results-on-august-4t-255b7bdd) — Source: PROCEPT BioRobotics
- 2026-05-28 12:00 EST — [PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval](https://biopharmsignal.com/news/PRCT/procept-biorobotics-advances-prostate-cancer-program-with-water-iv-study-enrollm-de942ff2) — Source: PROCEPT BioRobotics
- 2026-05-14 12:00 EST — [AUA Guidelines Strengthen Recommendation for Aquablation® Therapy](https://biopharmsignal.com/news/PRCT/aua-guidelines-strengthen-recommendation-for-aquablation-therapy-b17aee34) — Source: PROCEPT BioRobotics
- 2026-04-30 20:03 EST — [PROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & June](https://biopharmsignal.com/news/PRCT/procept-biorobotics-to-attend-three-upcoming-investor-conferences-in-may-june-336852ab) — Source: PROCEPT BioRobotics
- 2026-04-29 20:03 EST — [PROCEPT BioRobotics Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/PRCT/procept-biorobotics-reports-first-quarter-2026-financial-results-c24cd67e) — Source: PROCEPT BioRobotics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)